Cargando…
Combinational Therapy Enhances the Effects of Anti-IGF-1R mAb Figitumumab to Target Small Cell Lung Cancer
BACKGROUND: Small cell lung cancer (SCLC) is a recalcitrant malignancy with distinct biologic properties. Antibody targeting therapy has been actively investigated as a new drug modality. METHODS: We tested the expression of IGF-1R and calculated the survival in 61 SCLC patients. We also evaluated t...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Public Library of Science
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545894/ https://www.ncbi.nlm.nih.gov/pubmed/26287334 http://dx.doi.org/10.1371/journal.pone.0135844 |